Kristina Dada, PA
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,993 of the $7,306 with a category attached, or 82.0%. 29 manufacturers reported payments, led by AstraZeneca at 27.0% of the total. Among medical clinicians in NE with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 294 payments — averaging $24.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Pulmonx Corporation$1K
- Regeneron Healthcare Solutions, Inc.$446
- Grifols USA, LLC$440
- Boehringer Ingelheim$309
- Harmony Biosciences LLC$294
- plus $2K from 23 others
What the payments were for
- Travel & lodging$1,23217%
- Food & beverage$5,99382%
- Education$801%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 77 | $1,971 |
| Pulmonx Corporation | 5 | $1,396 |
| Regeneron Healthcare Solutions, Inc. | 26 | $446 |
| Grifols USA, LLC | 22 | $440 |
| Boehringer Ingelheim | 16 | $309 |
| Harmony Biosciences LLC | 16 | $294 |
| Jazz Pharmaceuticals Inc. | 15 | $273 |
| Insmed, Inc. | 13 | $266 |
| Amgen | 13 | $239 |
| Sanofi | 14 | $207 |
| Merck | 6 | $186 |
| United Therapeutics Corporation | 9 | $174 |
| Electromed, Inc. | 10 | $171 |
| GSK | 8 | $133 |
| Avadel CNS Pharmaceuticals, LLC | 7 | $122 |
| Actelion Pharmaceuticals US, Inc. | 5 | $105 |
| Axsome Therapeutics, Inc. | 5 | $89 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $77 |
| Mylan Specialty L.p. | 4 | $77 |
| Baxter Healthcare | 3 | $60 |
| Viatris Specialty LLC | 3 | $49 |
| Verona Pharma, Inc. | 3 | $45 |
| Bayer | 2 | $45 |
| Genentech USA, Inc. | 4 | $40 |
| Pharming Healthcare, Inc. | 1 | $31 |
| Mallinckrodt Hospital Products Inc. | 1 | $17 |
| Philips North America LLC | 1 | $16 |
| Lilly USA, LLC | 1 | $15 |
| Johnson & Johnson | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ZEPHYR ENDOBRONCHIAL VALVE$1,369
- FASENRA$746
- BREZTRI$746
- AIRSUPRA$540
- TEZSPIRE$540
- ANDEXXA$276
- CHARTIS CATHETER$136
- ZEPHYR DELIVERY CATHETER$136
- PULMONX CHARTIS TABLET CONSOLE$136
How this compares
$7,306 in reported general payments places this provider in the 90th percentile of 216 medical providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 203 | $168,142 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 88 | $45,852 |
| Dupixent PenDupilumab | 11 | $43,090 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 58 | $42,795 |
| Breo ElliptaFluticasone/Vilanterol | 25 | $11,590 |
| SymbicortBudesonide/Formoterol Fumarate | 34 | $8,346 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 12 | $7,038 |
| Spiriva HandihalerTiotropium Bromide | 12 | $6,184 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 15 | $3,128 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 106 | $2,979 |
| Azithromycin | 27 | $850 |
| Roflumilast | 12 | $822 |
| Montelukast Sodium | 46 | $236 |
| Prednisone | 49 | $235 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $133 | $225,584316 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,971 | $51,14092 claims |
| Boehringer IngelheimStiolto Respimat | $309 | $7,03812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 216 medical providers in Nebraska.
Other medical in Omaha
- Kelly HooverOmaha$16K
- Jacob RidderOmaha$12K
- Angelika StevensOmaha$8K
- Jennelea MontanezOmaha$8K
- Saundra BrennanOmaha$6K
- Collin HortonOmaha$6K
- Karla LessmanOmaha$5K
- Lynn McLaughlinOmaha$4K
- Hannah PickOmaha$4K
- Rebecca BertucciOmaha$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.